Antigen News and Research

RSS

New vaccination method aims at comprehensive protection against all known influenza mutations

One shot, protected forever: This would be a dream come true regarding influenza vaccinations. So far, vaccination against influenza did not provide a lasting protection.

13 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Pooling COVID-19 tests to detect future outbreaks

How could pooling SARS-CoV-2 tests help to detect future viral outbreaks? News-Medical spoke to Dr. Jean-François Rupprecht to find out more.

12 Mar 2021

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

A new study deals with the evaluation of adaptive immune response to COVID-19 vaccination in candidates who have recovered from SARS-CoV-2 infection.

11 Mar 2021

Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose

As the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, many countries have rolled out vaccines against the virus. In an encouraging preprint research paper posted to the medRxiv* server, scientists report on the vaccine efficacy in the Danish vaccination program.

10 Mar 2021

QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme

In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™.

From Rapid Labs Ltd 10 Mar 2021

Single mRNA vaccine dose may be enough for those previously exposed to SARS-CoV-2

New research supports the notion that those who have recovered from COVID-19, caused by SARS-CoV-2 infection, may only need one dose of an mRNA vaccine to boost immunity.

10 Mar 2021

mRNA COVID-19 vaccines show high efficacy in pregnancy and lactation

A reassuring study reports the immunogenicity and lack of reactogenicity of the coronavirus disease 2019 (COVID-19) vaccine when given to this group of subjects. This will contribute to the sum of knowledge about the implications of vaccination in this high-risk cohort.

10 Mar 2021

Tiny antibodies naturally generated by llamas can be effective against COVID-19

As the fight against COVID-19 continues, scientists have turned to an unlikely source for a potentially effective treatment: tiny antibodies naturally generated by llamas.

10 Mar 2021

New SARS-CoV-2 vaccine candidate produces strong immune response, prevents SARS-CoV-2 infection

A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.

10 Mar 2021

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

In a recent bioRxiv* preprint paper, researchers isolated anti-RBD nanobodies from llamas and “nanomice” (they engineered to produce VHHs cloned from alpacas, dromedaries and camels).

10 Mar 2021

Study: COVID-19 test package can reduce infections and mortality at justifiable cost

Mailing a package of SARS-CoV-2 tests to every household in America and asking people to use them once a week could greatly reduce total infections and mortality at a justifiable cost, a new study led by the Yale School of Public Health finds.

10 Mar 2021

2% of individuals carry 90% of SARS-CoV-2 virions: Study of 72,500 tests

In a new study published on the medRxiv* preprint server, researchers analyzed viral loads from pre-symptomatic and asymptomatic individuals in an extensive university surveillance program.

9 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.

8 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Immune cells in cerebrospinal fluid could be novel biomarkers of response to immune-based therapies

Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.

8 Mar 2021

FDA issues emergency use authorization for T-Detect COVID Test

Today, the U.S. Food and Drug Administration issued an emergency use authorization for the T-Detect COVID Test developed by Adaptive Biotechnologies.

5 Mar 2021

Antigen News and Research

New vaccination method aims at comprehensive protection against all known influenza mutations

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

Pooling COVID-19 tests to detect future outbreaks

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose

QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme

Single mRNA vaccine dose may be enough for those previously exposed to SARS-CoV-2

mRNA COVID-19 vaccines show high efficacy in pregnancy and lactation

Tiny antibodies naturally generated by llamas can be effective against COVID-19

New SARS-CoV-2 vaccine candidate produces strong immune response, prevents SARS-CoV-2 infection

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

Study: COVID-19 test package can reduce infections and mortality at justifiable cost

2% of individuals carry 90% of SARS-CoV-2 virions: Study of 72,500 tests

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

Researchers present fragment-based computational design of antibodies that target structured epitopes

Immune cells in cerebrospinal fluid could be novel biomarkers of response to immune-based therapies

FDA issues emergency use authorization for T-Detect COVID Test

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics